Impact of inferior pulmonary ligament dissection versus preservation during thoracoscopic upper lobectomy: a retrospective comparative analysis - Top-Institutions - MDSpire

Impact of inferior pulmonary ligament dissection versus preservation during thoracoscopic upper lobectomy: a retrospective comparative analysis

  • By

  • Xinhe Huang

  • Zheng Zhu

  • Baisheng Xie

  • Kaifei Chen

  • Yue Xie

  • Yi Zhu

  • April 20, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Thoracic Surgery
    • Oncology
    • Minimally Invasive Surgery

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Thoracic Surgery
    • Oncology
    • Pulmonology

  • #3

    Brigham and Women's Hospital
    Brigham and Women's Hospital

    Boston, MA

    Key Differentiators

    • Thoracic Surgery
    • Pulmonary Medicine
    • Minimally Invasive Surgery

  • #4

    University of Pittsburgh Medical Center (UPMC)
    University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, PA

    Key Differentiators

    • Thoracic Surgery
    • Oncology
    • Minimally Invasive Surgery

  • #5

    Shanghai Chest Hospital
    Shanghai Chest Hospital

    Shanghai, Shanghai

    Key Differentiators

    • Thoracic Surgery
    • Minimally Invasive Surgery
    • Lung Cancer

Original Source(s)

Impact of inferior pulmonary ligament dissection versus preservation during thoracoscopic upper lobectomy: a retrospective comparative analysis

  • by Xinhe Huang, Zheng Zhu, Baisheng Xie, Kaifei Chen, Yue Xie, Yi Zhu

  • April 20, 2026

Related Content

Imaging features of lung cancer with cystic airspaces: clinical utility, challenges, and perspectives

Autoantibodies combined with systemic inflammation markers for predicting bone metastases in non-small cell lung cancer patients

Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma